---
layout: default
title: Insulin Glargine
parent: 僅模型預測 (L5)
nav_order: 206
evidence_level: L5
indication_count: 10
---

# Insulin Glargine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the TxGNN drug-repurposing report template to generate a structured evaluation for insulin glargine. No skill invocation needed — this is direct content generation per the provided prompt spec, and the source data is limited (title uses `predicted_indications[0]`, which happens to be the weakest-evidence candidate).

---

# Insulin Glargine: From Diabetes Mellitus to Autoimmune Oophoritis

## One-Sentence Summary

> Insulin glargine is a long-acting basal insulin analogue established for glycaemic control in diabetes mellitus.
> The TxGNN model's top-ranked prediction is **Autoimmune Oophoritis**,
> but this candidate currently has **no supporting clinical trials** and **no supporting literature** — the association is flagged in the evidence pack itself as indirect (comorbidity-driven) rather than mechanistic.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Diabetes mellitus (established clinical use; not itemized as regulatory license text in this evidence pack) |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.88% (rank 1986 of model output) |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for insulin glargine in this evidence pack. Based on known information, insulin glargine is a long-acting basal insulin analogue used for glycaemic control in diabetes mellitus; its efficacy for that use is well established, but no MOA record was returned here to support a mechanistic case for autoimmune oophoritis.

The evidence pack's own rationale for this candidate states the link is likely mediated through **autoimmune polyglandular syndrome (APS)**, where type 1 diabetes and autoimmune oophoritis can co-occur in the same patient as separate autoimmune conditions — not because insulin glargine treats the ovarian autoimmune process itself. In other words, the model may be picking up a *comorbidity signal* (patients who have both conditions) rather than a *causal treatment relationship*.

Given this, the mechanism is explicitly labeled as indirect with no direct evidence, and no clinical trials or literature currently exist to corroborate it. This is a textbook case where a high TxGNN score should not be read as a validated pharmacological hypothesis without further mechanistic or clinical investigation.

## Clinical Trial Evidence

Currently no related clinical trials registered

## Literature Evidence

Currently no related literature available

## Germany Market Information

No marketing authorizations are on record in this evidence pack (market status: Not marketed; total licenses: 0).

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The top-ranked candidate (autoimmune oophoritis) is an L5 prediction — model output only, with zero clinical trials and zero literature support, and the evidence pack itself flags the mechanistic link as comorbidity-confounded rather than causal.
- Among the other 9 candidates reviewed, only **pancreatic agenesis** (rank 6) reaches L3 evidence, but its literature is largely general insulin-therapy background rather than disease-specific studies, and the "repurposing" is really standard replacement therapy for insulin-deficient states — not a novel mechanistic use. Two other candidates (drug-induced localized lipodystrophy, pressure-induced localized lipoatrophy) carry an explicit reversed-causality warning: insulin injection is a *known cause* of localized lipodystrophy, not a treatment for it, and should be treated as likely false positives rather than pursued.

**To proceed, the following is needed:**
- Insulin glargine's original MOA record (DG002, High severity — currently a data gap)
- TFDA/regulatory label warnings and contraindications (DG001, Blocking severity — currently a data gap)
- A targeted literature/trial search specifically on insulin glargine and autoimmune oophoritis (or APS-related ovarian autoimmunity) to test the comorbidity-vs-causation hypothesis
- Clarification of insulin glargine's original indication text and any regulatory licensing status, which are both currently empty in this evidence pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

